Funds › Prosight Management, LP
Prosight Management, LP
13F for Q3 2026, filed Nov 13, 2026. 32 positions worth $515.5M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$515.5M
−$64.9M (11.2%) vs Q2 2026
Positions
32
36 in Q2 2026
Top 10 share
70.6%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Prosight Management, LP in the latest 13F quarter?
Using 13F.ai, how has Prosight Management, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Prosight Management, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | LKFT Lakefront Biotherapeutics · ADR | 2.00M | $59.3M | 11.5% | -2.2% | 13F ↗ |
| 2 | STTK Shattuck Labs, Inc. | 7.65M | $52.2M | 10.1% | +28.4% | 13F ↗ |
| 3 | JANX Janux Therapeutics, Inc. | 2.94M | $50.9M | 9.9% | -22.6% | 13F ↗ |
| 4 | NKTR Nektar Therapeutics | 785,000 | $47.5M | 9.2% | -3.1% | 13F ↗ |
| 5 | ABVX Abivax SA · ADR | 376,794 | $37.3M | 7.2% | +251% | 13F ↗ |
| 6 | INSM Insmed Incorporated · Com Par $.01 | 238,088 | $27.2M | 5.3% | -36.6% | 13F ↗ |
| 7 | BSX Boston Scientific Corporation | 550,000 | $24.0M | 4.7% | -56.7% | 13F ↗ |
| 8 | IRTC iRhythm Holdings, Inc. | 200,980 | $22.8M | 4.4% | +21.4% | 13F ↗ |
| 9 | ALKS Alkermes plc | 550,000 | $22.3M | 4.3% | +39.5% | 13F ↗ |
| 10 | PRVA Privia Health Group, Inc. | 1.05M | $20.7M | 4.0% | New | 13F ↗ |
| 11 | MLYS Mineralys Therapeutics, Inc. | 800,000 | $20.1M | 3.9% | +77.9% | 13F ↗ |
| 12 | ZYME Zymeworks Inc. | 721,100 | $19.1M | 3.7% | +6.9% | 13F ↗ |
| 13 | SNDX Syndax Pharmaceuticals, Inc. | 812,582 | $15.3M | 3.0% | -32.3% | 13F ↗ |
| 14 | KURA Kura Oncology, Inc. | 1.27M | $13.7M | 2.6% | -36.9% | 13F ↗ |
| 15 | DNLI Denali Therapeutics Inc. | 550,700 | $11.4M | 2.2% | New | 13F ↗ |
| 16 | PRAX Praxis Precision Medicines, Inc. | 36,400 | $10.6M | 2.1% | New | 13F ↗ |
| 17 | HQY HealthEquity, Inc. | 115,796 | $10.2M | 2.0% | New | 13F ↗ |
| 18 | BBIO BridgeBio Pharma, Inc. | 150,000 | $9.9M | 1.9% | New | 13F ↗ |
| 19 | ALNY Alnylam Pharmaceuticals, Inc. | 37,000 | $9.1M | 1.8% | -62.3% | 13F ↗ |
| 20 | HUM Humana Inc. | 22,000 | $8.4M | 1.6% | New | 13F ↗ |
| 21 | ENOV Enovis Corporation | 267,432 | $4.9M | 0.9% | New | 13F ↗ |
| 22 | OKUR OnKure Therapeutics, Inc. | 1.33M | $3.6M | 0.7% | +35.4% | 13F ↗ |
| 23 | QTRX Quanterix Corporation | 825,000 | $3.1M | 0.6% | New | 13F ↗ |
| 24 | GENB Generate Biomedicines, Inc. | 144,756 | $2.2M | 0.4% | New | 13F ↗ |
| 25 | ANTX AN2 Therapeutics, Inc. | 350,877 | $1.9M | 0.4% | -26.1% | 13F ↗ |
| 26 | PLRX Pliant Therapeutics, Inc. | 1.60M | $1.7M | 0.3% | +17.1% | 13F ↗ |
| 27 | RCKT Rocket Pharmaceuticals, Inc. | 595,024 | $1.6M | 0.3% | -15.0% | 13F ↗ |
| 28 | RNTX Rein Therapeutics, Inc. | 1.66M | $1.3M | 0.3% | +50.9% | 13F ↗ |
| 29 | COYA Coya Therapeutics, Inc. | 229,600 | $1.2M | 0.2% | +35.1% | 13F ↗ |
| 30 | CRBP Corbus Pharmaceuticals Holdings, Inc. | 168,383 | $1.1M | 0.2% | -74.1% | 13F ↗ |
| 31 | IMRX Immuneering Corporation | 150,000 | $614.3K | 0.1% | +307% | 13F ↗ |
| 32 | ADCT ADC Therapeutics SA | 399,900 | $487.9K | 0.1% | -94.9% | 13F ↗ |
Changes since Q2 2026
9 new, 11 added to, 12 trimmed, 13 exited, 0 unchanged. By estimated dollars.
New positions (9)
| PRVA Privia Health Group, Inc. | 1.05M | New | $20.7M |
| DNLI Denali Therapeutics Inc. | 550,700 | New | $11.4M |
| PRAX Praxis Precision Medicines, Inc. | 36,400 | New | $10.6M |
| HQY HealthEquity, Inc. | 115,796 | New | $10.2M |
| BBIO BridgeBio Pharma, Inc. | 150,000 | New | $9.9M |
| HUM Humana Inc. | 22,000 | New | $8.4M |
| ENOV Enovis Corporation | 267,432 | New | $4.9M |
| QTRX Quanterix Corporation | 825,000 | New | $3.1M |
| GENB Generate Biomedicines, Inc. | 144,756 | New | $2.2M |
Added to (11)
| ABVX Abivax SA · ADR | 376,794 | +251% | $26.7M |
| STTK Shattuck Labs, Inc. | 7.65M | +28.4% | $11.5M |
| MLYS Mineralys Therapeutics, Inc. | 800,000 | +77.9% | $8.8M |
| ALKS Alkermes plc | 550,000 | +39.5% | $6.3M |
| IRTC iRhythm Holdings, Inc. | 200,980 | +21.4% | $4.0M |
| ZYME Zymeworks Inc. | 721,100 | +6.9% | $1.2M |
| OKUR OnKure Therapeutics, Inc. | 1.33M | +35.4% | $944.4K |
| IMRX Immuneering Corporation | 150,000 | +307% | $463.3K |
| RNTX Rein Therapeutics, Inc. | 1.66M | +50.9% | $450.4K |
| COYA Coya Therapeutics, Inc. | 229,600 | +35.1% | $298.6K |
Trimmed (12)
| BSX Boston Scientific Corporation | 550,000 | -56.7% | -$31.4M |
| INSM Insmed Incorporated · Com Par $.01 | 238,088 | -36.6% | -$15.7M |
| ALNY Alnylam Pharmaceuticals, Inc. | 37,000 | -62.3% | -$15.1M |
| JANX Janux Therapeutics, Inc. | 2.94M | -22.6% | -$14.9M |
| ADCT ADC Therapeutics SA | 399,900 | -94.9% | -$9.1M |
| KURA Kura Oncology, Inc. | 1.27M | -36.9% | -$8.0M |
| SNDX Syndax Pharmaceuticals, Inc. | 812,582 | -32.3% | -$7.3M |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 168,383 | -74.1% | -$3.3M |
| NKTR Nektar Therapeutics | 785,000 | -3.1% | -$1.5M |
| LKFT Lakefront Biotherapeutics · ADR | 2.00M | -2.2% | -$1.3M |
Exited (13)
| VEEV Veeva Systems Inc. | 106,200 | Exited | -$18.8M |
| Crinetics Pharmaceuticals In | 374,666 | Exited | -$14.0M |
| ICUI ICU Medical, Inc. | 51,000 | Exited | -$7.5M |
| ISRG Intuitive Surgical, Inc. | 17,000 | Exited | -$6.8M |
| PRCT PROCEPT BioRobotics Corporation | 268,269 | Exited | -$6.1M |
| WGS GeneDx Holdings Corp. | 85,500 | Exited | -$5.9M |
| OPCH Option Care Health, Inc. | 270,716 | Exited | -$5.7M |
| EBS Emergent BioSolutions Inc. | 459,952 | Exited | -$3.9M |
| PFE Pfizer, Inc. | 135,366 | Exited | -$3.3M |
| KIDS OrthoPediatrics Corp. | 157,500 | Exited | -$3.0M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 32 | $515.5M | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 36 | $580.4M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 46 | $609.8M | Current | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 38 | $483.9M | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 42 | $428.8M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 39 | $410.1M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 38 | $304.3M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer